Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects Blymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center & post germinal center B-cells.
The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter’s transformation), follicular lymphoma, and marginal zone lymphoma.
DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan-B-cell antigens, such as CD20 and CD79a.
Currently, the primary challenges in the research for DLBCL are to identify molecular subsets accurately and to determine if specific chemotherapy platforms and targeted agents offer the differential benefit with the ultimate goal of maximizing initial cure rates to improve long-term survival while minimizing toxicity. Consequently, some of targeted therapies and cell therapies have already been approved or the treatment for DLBCL, while many are in the clinical stage of development which have demonstrated excellent initial outcomes and are in the process of further clinical evaluation.
Get FREE sample copy at:
The Diffuse Large B-cell Lymphoma market report also covers emerging drugs, current treatment practices, Diffuse Large B-cell Lymphoma market share of the individual therapies, current and forecasted Diffuse Large B-cell Lymphoma Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Diffuse Large B-cell Lymphoma Market Key Facts
The total incident cases of DLBCL in the 7MM was assessed to be 67,743 in 2017, and are expected to increase during the study period (2017-2030).
It was observed that the age-group with the highest incidence among the 7MM was 65– 74 years in 2017. Patients of age group 55–64 years were observed to be the second-highest in 2017.
Among the EU5 countries, Germany had the highest incident population of DLBCL with 7,443 cases, followed by the United Kingdom and France, while Spain had the lowest incident cases in 2017.
Japan had 9,485 cases for DLBCL in 2017, which accounted for nearly 14% of the total 7MM patient population of DLBCL.
Key Benefits of Diffuse Large B-cell Lymphoma Market Report
Diffuse Large B-cell Lymphoma market report provides an in-depth analysis of Diffuse Large B-cell Lymphoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Diffuse Large B-cell Lymphoma market report will help in developing business strategies by understanding the Diffuse Large B-cell Lymphoma Market trends & developments, key players and future market competition that will shape and drive the Diffuse Large B-cell Lymphoma market in the upcoming years.
The Diffuse Large B-cell Lymphoma market report covers Diffuse Large B-cell Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Diffuse Large B-cell Lymphoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
There are several treatment options for B-cell lymphoma, which include chemotherapy, radiation, and immunotherapy. The choice of treatment option is dependent on the symptoms, age, and how fast it is growing and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies. Chemotherapy is the main way to treat most types of B-cell NHL. A combination of chemotherapy and the monoclonal antibody rituximab (Rituxan), with or without radiation therapy, can lead to disease remission in a large number of patients with this form of lymphoma.
The Diffuse Large B-cell Lymphoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Diffuse Large B-cell Lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Diffuse Large B-cell Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
There is an observed difference in the gender, and cases occurs more frequently in male population as compared to female. In 2017, males affected by the disease were nearly 56% of the DLBCL cases in the US, which is equivalent to 40,122 cases in comparison to the females. As per DelveInsight’s assessment, the overall cases of DLBCL in both the genders are expected to increase in the coming years.
The Diffuse Large B-cell Lymphoma epidemiology section covers insights about historical and current Diffuse Large B-cell Lymphoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Diffuse Large B-cell Lymphoma Drugs Uptake and Key Market Players
The Diffuse Large B-cell Lymphoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diffuse Large B-cell Lymphoma market or expected to get launched in the market during the study period. The analysis covers Diffuse Large B-cell Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
There are many companies involved in the development for various therapies for the frontline, second line (transplant-eligible and transplant ineligible) and subsequent R/R patients with DLBCL.
Some of the key players in the Diffuse Large B-cell Lymphoma Market includes:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Diffuse Large B-cell Lymphoma Competitive Intelligence Analysis
4. Diffuse Large B-cell Lymphoma Market Overview at a Glance
5. Diffuse Large B-cell Lymphoma Disease Background and Overview
6. Diffuse Large B-cell Lymphoma Patient Journey
7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population
8. Diffuse Large B-cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Diffuse Large B-cell Lymphoma Unmet Needs
10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment
11. Diffuse Large B-cell Lymphoma Marketed Products
12. Diffuse Large B-cell Lymphoma Emerging Therapies
13. Diffuse Large B-cell Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Diffuse Large B-cell Lymphoma Market Outlook (7 major markets)
16. Diffuse Large B-cell Lymphoma Access and Reimbursement Overview
17. KOL Views on the Diffuse Large B-cell Lymphoma Market.
18. Diffuse Large B-cell Lymphoma Market Drivers
19. Diffuse Large B-cell Lymphoma Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Diffuse Large B-cell Lymphoma – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Diffuse Large B-cell Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Diffuse Large B-cell Lymphoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States